Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Report 2026: Poised For Transformation Through 2036 As Pegcetacoplan, Iptacopan, And SGB-9768 Advance
The immune complex membranoproliferative glomerulonephritis (IC-MPGN) market across the seven major markets-the United States, Germany, France, Italy, Spain, the United Kingdom and Japan-was valued at approximately USD 30 million in 2025. The market is projected to expand at a compound annual growth rate of approximately 26% from 2026 to 2036, supported by targeted therapy adoption, improved diagnosis, increased disease awareness and continued clinical development.
The United States represented the largest IC-MPGN market in 2025, accounting for approximately USD 20 million. Overall growth is expected to accelerate as treatment moves beyond supportive care and broad immunosuppression toward complement-targeted therapies addressing underlying disease mechanisms.
IC-MPGN Epidemiology and Patient Burden
Approximately 7,000 diagnosed prevalent IC-MPGN cases were estimated across the 7MM in 2025. The United States accounted for nearly 3,500 cases, followed by Japan. Adults represented the majority of the diagnosed population, with approximately 3,400 adult cases reported in the United States compared with about 10% of cases occurring in pediatric patients. Males accounted for more than half of US cases.
UK registry evidence indicates a minimum point prevalence of 1.3 cases per 100,000 people for membranoproliferative glomerulonephritis. Disease progression remains a major concern, with up to 30-35% of patients with C3 glomerulopathy or idiopathic IC-MPGN potentially developing kidney failure within 10 years of diagnosis. This clinical burden creates a substantial need for earlier diagnosis and therapies capable of preserving kidney function.
Diagnosis and Current IC-MPGN Treatment Landscape
IC-MPGN diagnosis integrates clinical assessment, laboratory findings, histopathology and immunofluorescence. Kidney biopsy remains the diagnostic standard, supporting differentiation according to immune complex deposition, complement involvement, mesangial proliferation and capillary wall changes. Evaluation may also identify secondary causes, including chronic infections, autoimmune disorders, monoclonal gammopathy and malignancies. Idiopathic disease is classified only after a comprehensive assessment excludes an underlying cause.
Traditional IC-MPGN management has focused on reducing proteinuria, controlling hypertension and edema, managing dyslipidemia and slowing kidney deterioration. Common interventions include renin-angiotensin-aldosterone system blockade with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, corticosteroids, other immunosuppressive agents and lipid-lowering therapies. Treatment selection varies according to disease severity, kidney function, proteinuria and the presence of an associated condition.
Approved IC-MPGN Therapy
Pegcetacoplan (EMPAVELI), developed by Apellis Pharmaceuticals, is a targeted complement C3 inhibitor approved by the US Food and Drug Administration in July 2025 for patients aged 12 years and older with primary IC-MPGN to reduce proteinuria. The approval was based on positive six-month findings from the Phase III VALIANT study.
VALIANT included pediatric and adult patients with native and post-transplant kidneys. According to reported results, pegcetacoplan produced a 68% reduction in proteinuria, stabilized kidney function and substantially reduced C3 deposits compared with placebo. Publication of the study findings in The New England Journal of Medicine in December 2025 reinforced the clinical relevance of complement inhibition in IC-MPGN.
In March 2026, Biogen and Apellis Pharmaceuticals announced a definitive agreement under which Biogen agreed to acquire Apellis. The transaction represents a notable strategic development within the complement-targeted therapeutics landscape.
IC-MPGN Pipeline and Competitive Landscape
The IC-MPGN pipeline is increasingly centered on alternative complement pathway modulation. Prominent emerging therapies include Novartis' iptacopan and SanegeneBio's SGB-9768, both of which may broaden future treatment options and intensify competition during the latter half of the forecast period.
- Iptacopan (LNP023), Novartis: An oral complement factor B inhibitor in the Phase III APPARENT study for idiopathic IC-MPGN. According to the company's February 2026 investor presentation, a clinical data readout is anticipated in 2028. Its oral route and targeted alternative pathway inhibition may support adoption if the study demonstrates favorable efficacy and safety. SGB-9768, SanegeneBio: A GalNAc-conjugated RNA interference candidate designed to silence C3 messenger RNA in hepatocytes. The therapy is in Phase II clinical development for IC-MPGN. Phase I findings showed dose-dependent and sustained reductions in serum C3 and complement pathway activity, together with a favorable safety and tolerability profile. SGB-9768 received FDA Orphan Drug Designation for IC-MPGN in February 2026.
Complement C3 and factor B inhibitors define the principal innovation landscape within the current IC-MPGN market. Pegcetacoplan inhibits complement activation at C3, while iptacopan targets factor B to reduce alternative pathway activity. SGB-9768 offers a differentiated RNA interference strategy intended to lower circulating C3 levels.
Key IC-MPGN Market Growth Drivers
- High unmet medical need: IC-MPGN continues to carry a significant risk of chronic kidney disease, dialysis, transplantation and kidney failure. Targeted therapy adoption: The approval of pegcetacoplan has established complement inhibition as a therapeutic strategy and may support further investment in mechanism-based treatments. Improved diagnostic practices: Greater use of kidney biopsy, immunofluorescence and complement testing is improving differentiation between IC-MPGN and C3 glomerulopathy. Expanding clinical pipeline: Mid- and late-stage candidates may increase treatment choice, improve administration convenience and reshape market share. Greater disease awareness: Increased recognition among nephrologists and other specialists is expected to support diagnosis and treatment rates.
Market Access, Pricing and Drug Uptake
Drug adoption will depend on efficacy, safety, route and frequency of administration, clinical positioning, payer coverage and the ability to demonstrate long-term preservation of kidney function. Pegcetacoplan is expected to achieve measured uptake based on its approved status and complement-targeted mechanism. Iptacopan may follow a gradual-to-moderate uptake trajectory, subject to positive Phase III findings and regulatory review, while SGB-9768 could provide an additional treatment approach if ongoing studies confirm its clinical profile.
Pricing and reimbursement will remain central to commercial performance. Country-level assessments cover therapy accessibility, cost-effectiveness, payer policies, patient assistance initiatives and out-of-pocket exposure. In the United States, reimbursement decisions are expected to reflect the relationship between treatment costs and outcomes such as reduced proteinuria, preserved kidney function and delayed progression to dialysis or transplantation.
IC-MPGN Market Report Coverage
The report provides historical and forecast analysis from 2022 through 2036. It evaluates diagnosed prevalence, patient segmentation, treatment practices, market size, therapy-specific revenue, market share, drug uptake and competitive developments across the 7MM.
The report also includes profiles of approved and emerging therapies, clinical trial analysis, regulatory milestones, patents, collaborations, strategic partnerships and anticipated market catalysts. Primary research incorporates perspectives from more than 10 key opinion leaders and subject-matter experts affiliated with institutions including Stanford University, the University of Wurzburg and the Cardiovascular Prevention Institute.
Additional analysis includes epidemiology-based bottom-up forecasting, SWOT analysis, conjoint analysis, treatment-addressable market estimates, peak patient share projections, pricing and analogue assessment, market access considerations and country-specific opportunities. These insights support pharmaceutical companies, investors, healthcare providers and other stakeholders in evaluating the evolving IC-MPGN treatment and commercial landscape.
Strategic Outlook
The IC-MPGN market is entering a period of substantial change. The introduction of pegcetacoplan, continued development of iptacopan and SGB-9768, and growing recognition of complement-mediated disease mechanisms are expected to transform treatment strategies through 2036. Although diagnostic delays, limited therapeutic options and progression to kidney failure remain important unmet needs, continued innovation may improve patient outcomes while creating significant opportunities across the United States, Europe and Japan.
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen (Apellis pharmaceuticals)Swedish Orphan Biovitrum AB SanegeneBio Novartis
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment